Citations

Mayo Clinic

Showing 10 of 108551 citations.

0665 Does Exercise Have an Effect on Daytime Sleepiness?
Patel, Anshum , Cheung, Joseph

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A284-A285

10.1093/sleep/zsae067.0665 Get It

Abstract Introduction Regular exercise improves sleep quality by reducing sleep onset latency, extending total sleep duration, and enhancing sleep efficiency, which may alleviate daytime sleepiness. However, the specific impact of exercise on daytime sleepiness remains unclear, with conflicting findings in the literature. We analyzed existing interventional studies which used Epworth Sleepiness Scale (ESS) to measure changes in degree of daytime sleepiness before and after an exercise regimen, allowing us to explore the relationship between exercise and daytime sleepiness. Methods Following PRISMA guidelines, a systematic search was conducted in electronic database of PubMed and Google Scholar from 1991 to the present. Thorough screening and inclusion criteria were applied to identify relevant studies which included ESS assessment before and after an exercise intervention. Also assessed sleep quality by Pittsburgh Sleep Quality Index (PSQI). Results Seven studies met all the inclusion criteria and were included in this study. Exercise exhibited a significantly beneficial impact on sleepiness measured by ESS in four out of seven studies we included in review while two studies showed a marginal reduction in ESS without statistical significance, and one study indicated no change. Additionally, exercise showed an improvement in sleep quality in four out of five studies that included PSQI. Variability in results was noted, influenced by factors such as exercise type, intensity, duration, and timing, as well as individual adherence. Additionally, exercise interventions improved sleep quality, as suggested by reduced scores in PSQI which may indirectly improve daytime sleepiness. Conclusion This analysis of existing interventional studies on exercise and daytime sleepiness suggests exercise can be beneficial for reducing daytime sleepiness and improving sleep quality. While the exact mechanism remains elusive, several factors contribute to the impact of both acute and chronic exercise on daytime sleepiness such as improved sleep quality, regulation of circadian rhythm, neurotransmitters release, stress reduction, increased energy levels, and weight reduction ultimately alleviating daytime sleepiness. Future research will be essential for addressing gaps on how exercise regimen and the underlying mechanisms may prove efficacious on improving daytime sleepiness. Support (if any) Mayo Clinic Florica Research Accelerator for Clinicians Engaged in Research Program
0558 Could Treatment of Sleep Apnea Worsen Somnolence?
Balasubramanian, Prasanth , Khalil, Melissa, Arunthari, Vichaya, Colaco, Brendon

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A239-A239

10.1093/sleep/zsae067.0558 Get It

Abstract Introduction Patients presenting with daytime somnolence need to be evaluated for common etiologies including sleep-related breathing disorders, shift work disorder, insufficient sleep, insomnia and disorders of hypersomnolence. Sleep disordered breathing (SDB) is one of the most common causes of daytime sleepiness. We postulate that treatment of SDB may actually worsen symptoms, if associated with poor sleep due to positive airway pressure (PAP) therapy. Methods N/A Results A 49-year-old female presented to our clinic with increased daytime somnolence. She was diagnosed with obstructive sleep apnea (OSA) at an outside center 3 years ago and was started on auto PAP therapy with pressure settings at 6-10 cmH2O. She had 100% usage, 95th percentile pressure of 9 cm H2O, and a residual Apnea Hypopnea Index (AHI) of 1.1. The patient reported excessive daytime sleepiness, with an Epworth Sleepiness Scale of 16, requiring a daily 3-hour nap. Further sleep history revealed that she had multiple nocturnal awakenings due to discomfort with PAP therapy, including mask related issues causing sleep disruption. Several mask adjustments did not result in any sleep improvement. We decided to re-evaluate her with an in-lab polysomnography. Diagnostic data revealed an overall AHI of 1.6, supine AHI of 12.0, and lateral AHI of 1.5. Mean oxygen saturation was 94.6% with a nadir of 89.0%. The patient was advised to discontinue PAP therapy, and to sleep on her sides, which led to improvement in her sleep quality and daytime sleepiness. Conclusion Positional OSA, defined by greater than 50% increase in AHI in supine position compared to non-supine position, with or without AHI less than 5 in non-supine position, is seen in up to 50-60% of patients with OSA. In addition, intolerance to CPAP has been noted in 29-83% of patients. We need to be clinically aware of the potential effect of PAP devices, or oral appliances, on sleep disruption among intolerant patients. Among this group, conservative therapies like positional therapy or weight loss may be more effective for symptom management, especially for mild SDB. Support (if any)
0511 High Frequency Radar for Non-Contact Detection of Respiratory Signals During Sleep
Goswami, Umesh , Kablan, John, Condon, John P., Goswami, Umesh

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A219-A220

10.1093/sleep/zsae067.0511 Get It

Abstract Introduction Polysomnography (PSG) requires on-body sensors for respiratory effort measurement, that can adversely affect sleep quality and accuracy of detection of sleep related breathing disorders (SRBD). We developed a non-contact 60 Hz pulsed wave radar system with integrated advanced signal processing to collect respiratory effort, heart rate and gross body movements data using phase differencing to a sub-mm resolution. In this study we tested the performance of this system in detecting SRBD events against standard PSG in human participants. Methods During participants’ clinically indicated PSG, we collected concurrent data from the radar system placed under the bed on a tripod mount. Algorithms were developed to quantify breath amplitude reductions collected by radar and compared to the time-synced signals derived from respiratory impedance plethysmography belts. A Convolutional Neural Network (CNN) was trained on radar in-phase/quadrature (I/Q) data for each 30 second epoch to output probability of apnea and hypopnea events using standard event definitions. Receiver Operating Characteristics (ROC) plot and confusion matrix for the trained network were generated to provide accuracy of event predictions. Results A total of 60 participants completed the study. The participants had a mean age of 65 years (Inter Quartile Range 13.5 years), and 56% subjects were male. The mean AHI for the entire cohort was 12.9 (IQR 14.75) events/hour. ROC plots showed an Area Under the Curve (AUC) of 0.98 for events detection by radar compared to human scored PSGs. The confusion matrix was generated at an operating point of 95% sensitivity and 80% specificity. Conclusion The non-contact high frequency radar system showed excellent performance in respiratory event detection in patients with sleep-related breathing disorders in comparison to the gold standard PSG system. Use of this technology is expected to reduce the number of body contact sensors used during conventional sleep studies and thus improve patient comfort and accuracy of results. Support (if any) Research reported in this abstract was supported by National Institute of Aging of the NIH under award number: R44AG060779
0605 Temporomandibular and Oral Parafunction as Risk Factors for Jaw Pain Related to Oral Appliance Therapy
Hamza, Amina, Giri, Subha , Morgenthaler, Timothy I.

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A258-A259

10.1093/sleep/zsae067.0605 Get It

Abstract Introduction Oral Appliance Therapy (OAT) is a management option for patients with Obstructive Sleep Apnea (OSA). A reported drawback to OAT is symptoms relating to Temporomandibular Joint Disorder (TMD), including post-procedure jaw pain. Some studies reported TMD in over 50% of patients prior to OAT. The aim of this study was to evaluate the prevalence of TMD and oral Parafunction Habits (PFH) in patients with OSA referred for OAT, and determine any relationship between patient characteristics, demographics, medical history, and degree of OAT advancement with post-procedure jaw pain. Methods A retrospective analysis was conducted, reviewing the electronic health records of 125 patients with OSA referred to the division of dental sleep medicine in Mayo Clinic Rochester, for OAT. Records reviewed included patient demographics, TMD-PFH symptoms and signs before and after initiation of OAT, self-reported history of, and signs of PFH, AHI pre-initiation of OAT, presence of fibromyalgia, SSRI use, and percent advancement of appliance at time of re-evaluation. Results The median age of patients reviewed was 58 (Interquartile Range (IQR) 20), median BMI 30.5 (IQR 7), median AHI 11.3 (IQR 9.5). 57% were male, 43% female. 20.8% patients had TMD history, 37.6% had TMD signs, 47.2% had PFH history (jaw clenching, lip biting, and/or thumb sucking). 96% had signs of PFH. 15.2% reported post-procedure jaw pain. There was a statistically significant relationship between both TMD history and TMD signs, with post-procedure jaw pain (p value 0.002 and 0.013 respectively), although after multi-variate analysis, only TMD history remained associated with post-procedure jaw pain (Odd’s Ratio 3.385, 95% Confidence Interval 1.081 – 10.601, p value = 0.036). Age, BMI, gender, PFH signs and history, SSRI use, fibromyalgia history, % advancement of OA had no statistical association with post-procedure jaw pain. Conclusion Having a history of TMD symptoms prior to OAT is a risk factor for post-OAT jaw pain. A thorough oral and maxillofacial history in patients being considered for OAT is important to identify patients with TMD history, to establish a clear path to initiate OAT and to closely monitor, reduce or potentially eliminate the reported side effect. Support (if any)
0706 Dextromethorphan for Restless Legs Syndrome: Testing the Glutamate Theory
Khalil, Melissa, Dredla, Brynn K., Cheung, Joseph , Castillo, Pablo R.

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A302-A302

10.1093/sleep/zsae067.0706 Get It

Abstract Introduction Restless legs syndrome (RLS) is a common disorder of unpleasant sensations during inactivity, an urge to move the legs, and hyperarousal. The pathophysiology is incompletely understood. Treatments are not always successful or carry side effects. Methods (Case Report) Results A 45-year-old woman presented with over a decade of RLS and sleep-onset insomnia. The diagnosis was based on the International RLS Study Group criteria. The severity was assessed by the nightly occurrence and Insomnia Severity Index (ISI) of 25. Interfering neurologic or sleep disorders, medications, and abnormal blood work were ruled out. Different dopamine agonists resulted in augmentation. Caffeine was stopped. Polysomnography revealed periodic limb movement with sleep fragmentation. Gabapentin was partially effective and poorly tolerated at high doses, but continued at 600 mg. While using Dextromethorphan (DXM) for an upper respiratory infection, the patient found dramatic improvement of her RLS symptoms. Independently, she discontinued Gabapentin, and continued DXM 30 mg for 6 months, with consistent improvement. ISI decreased to 10. Ultimately, considering its expense, DXM was tapered, and Tramadol initiated. The pathophysiology of RLS is partially understood. Studies showed abnormalities in iron regulation, low adenosine tone, enhanced glutamatergic activity, inflammation, and a genetic predisposition, as contributing factors. Alpha-2-delta calcium channel ligands inhibit the presynaptic glutamate release. Central nervous system iron deficiency may increase glutamatergic tone. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, inhibits the activation of NMDA receptor by glutamate and decreases glutamate presynaptic release. Ketamine was reported to effectively treat RLS. DXM, another NMDA receptor antagonist, has not been reported to treat RLS in the literature. Additionally, an association between inflammation and RLS was described, and limited data showed anti-inflammatory effect of DXM. Conclusion Patients with RLS suffer from their symptoms’ burden. Approved medications could carry side effects, or augmentation. We report a case of severe RLS with dramatic and sustained improvement with DXM. Support (if any)
0768 Poor Sleep Quality Increases Mortality Risk. a Population-based Longitudinal Prospective Study in Adults
Khalil, Melissa, Brutto, Oscar Del, Rumbea, Denisse, Sedler, Mark J. , Mera, Robertino M. , Castillo, Pablo

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A329-A329

10.1093/sleep/zsae067.0768 Get It

Abstract Introduction Sleep-related symptoms have been associated with adverse health outcomes, including increased mortality risk. Studies that analyzed the correlation between sleep and mortality focused on the single effect of self-reported sleep duration or relied on nonstructured questionnaires about sleep. In order to evaluate the detrimental effects of sleep disorders, studies should be based on well-structured and validated questionnaires that inquire about different components of sleep, including sleep quality. In addition, taking into consideration the fluctuations in sleep duration over the study period is essential. We aimed to assess the association between sleep quality and all-cause mortality in community-dwelling adults living in rural Ecuador. Methods Individuals aged ≥40 years enrolled in the prospective population-based Three Villages Study cohort were included. Sleep quality was assessed by means of the Pittsburgh Sleep Quality Index (PSQI). Study participants were evaluated at baseline and at every annual door-to-door survey until they remained enrolled in the study. Mixed models Poisson regression for repeated PSQI determinations and multivariate Cox-proportional hazards models were fitted to estimate mortality risk according to sleep quality. Results Analysis included 1494 individuals (mean age: 56.6 ± 12.5 years; 56% women) followed for a median of 6.3 ± 3.3 years. At baseline, 978 (65%) individuals had good sleep quality and 516 (35%) had poor sleep quality. The effects of PSQI scores changing over time on mortality was confounded by the impact of the SARS-CoV-2 pandemic on both. One hundred ninety-five individuals (13%) died during the follow-up, resulting in a crude mortality rate of 1.58 per 100 person years (95% C.I.: 1.27-1.88) for individuals with good sleep quality, and 3.18 (95% C.I.: 2.53-3.82) for those with poor sleep quality at baseline. A multivariate Cox-proportional hazards model showed that individuals with poor sleep quality at baseline were 1.38 times (95% C.I.: 1.02-1.85) more likely to die compared to those with good sleep quality; in this model, increased age, poor physical activity, and high fasting glucose remained significant. Conclusion Poor sleep quality is associated with increase mortality risk among middle-aged and older adults. Support (if any)
0468 CRASH: Cancer Reoccurrence Is Accelerated by Episodic Hypoxemia
Rodriguez, Fernando Figueroa , Peikert, Tobias, Escalante, Patricio , Lim, Kaiser G. , Morgenthaler, Timothy I.

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A201-A202

10.1093/sleep/zsae067.0468 Get It

Abstract Introduction Several studies have shown a positive association between Obstructive Sleep Apnea (OSA) and malignancies such as lung cancer. However, the effects of intermittent hypoxemia in cancer-free survival following curative therapy are not known. We propose that OSA-related episodic hypoxemia and hypoxic burden are independent risk factors for accelerated lung cancer reoccurrence (< 2 years). Methods We performed a retrospective record review of patients 18 years and older from January 2016 to September 2023 with history of non-small cell lung cancer who received an overnight oximetry study (OXY) within three years prior to undergoing curative malignancy treatment. Subjects with history of central sleep apnea, baseline oxygen saturation (SpO2) below 90%, receiving supplemental oxygen or treatment for OSA were excluded. Results 403 patients met inclusion criteria (52% female vs 48% males; median age 74 y). The most common histologic subtypes were adenocarcinoma (68%) followed by squamous cell carcinoma (22%). Most patients fell into Stage IA1 (35%) followed by IA2 (24.1%) and IB (19%) as per TNM 8th edition classification. Over this period, 68 patients (22%) had lung cancer recurrence (median 19 months). A 4% oxygen desaturation index (ODI) of >15 and time spent in desaturation events were found to be a risk factor for cancer reappearance in less than 2 years (p< 0.001). Measures of hypoxic burden such as time spent below 89% SpO2, average SpO2 value below 89%, and single nadir oxygen levels, showed a similar association (p< 0.001). This was irrespective of histologic subtype, stage at diagnosis, and all studied demographic variables. Basal SpO2 demonstrated no correlation. A multivariate proportional hazard survival model showed that ODI>15 was no longer significant, however average SpO2 below 89% and single minimum oxygen level remained strongly correlated with accelerated recurrence. Conclusion This study showed a strong, positive association between accelerated lung cancer recurrence and OSA-related episodic hypoxemia and hypoxic burden on our univariate analysis. The multivariate model demonstrated correlation with hypoxic load measures only, suggesting the need for a larger sample to elucidate the involvement of this highly treatable risk factor. To our knowledge, this is the first study revealing this potential link. Support (if any)
0632 Design Elements for a Switch Study from High- to Low-Sodium Oxybate Evaluating Blood Pressure in Narcolepsy (XYLO)
White, William B. , Macfadden, Wayne , Baranak, Christine, Nichols, Deborah A. , Akerman, Sarah , Somers, Virend K.

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A270-A270

10.1093/sleep/zsae067.0632 Get It

Abstract Introduction High sodium intake can increase blood pressure (BP) and future cardiovascular risk. Individuals with narcolepsy have an elevated cardiovascular comorbidity burden before considering medication-specific risks. Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration (FDA) to treat excessive daytime sleepiness or cataplexy in patients ≥7 years of age with narcolepsy and idiopathic hypersomnia in adults. LXB has the same active moiety as high-sodium oxybates (sodium oxybate [SXB, Xyrem®] and fixed-dose SXB [Lumryz™]) but contains 92% less sodium. The objective of XYLO is to measure ambulatory and in-clinic systolic BP (SBP) changes after switching to LXB from a high-sodium oxybate in participants with narcolepsy (NCT05869773). Methods This 6-week, open-label, multicenter, switch study is enrolling participants 18–70 years of age with narcolepsy (type 1 or 2) taking 6–9 g/night of high-sodium oxybate for ≥6 weeks. Hybrid enrollment supports both on-site and decentralized (monitored at the participant’s home by mobile health professionals) participation, and may broaden the pool of eligible participants. After ≥2 weeks on stable high-sodium oxybate dose/regimens (screening period), participants switch to the same dose/regimen of LXB for 6 weeks (intervention period). The primary endpoint is the change in 24-hour SBP from baseline (the most recent screening measurement prior to switching) to the end-of-treatment visit (approximately 6 weeks after switching) measured via 24-hour ambulatory BP monitoring (ABPM). Secondary endpoints evaluate change from baseline to end-of-treatment visit in-clinic SBP, as well as daytime average SBP and nighttime average SBP measured via 24-hour ABPM. Results Recruitment began in June 2023. This study uses a group sequential design with an adaptive sample size target of 57–77 participants completing the 6-week intervention period. This design provides 90% power to detect a mean difference of 3.5 mmHg (a clinically relevant change) in 24-hour SBP (assuming a standard deviation of the differences in 24-hour SBP of 8 mmHg). Conclusion XYLO will enable the assessment of 24-hour BP changes following transition from a high-sodium oxybate to LXB. Planned hybrid enrollment with a decentralized option may increase study access leading to a more diverse clinical trial population. Support (if any) Jazz Pharmaceuticals
0722 Clinical, Demographic, Functional, and Symptom Correlates of COMISA in Stable Heart Failure
LaFleur, Kelley, Wang, Zequan , LaFleur, Kelley, Jeon, Sangchoon , Conley, Samantha , Redeker, Nancy S.

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A309-A309

10.1093/sleep/zsae067.0722 Get It

Abstract Introduction Sleep disordered breathing (SDB: obstructive & central sleep apnea) and insomnia are common in heart failure (HF). However, most studies have not addressed the presence of combined SDB and insomnia (COMISA). The purposes of this study were to (1) describe COMISA among adults with stable chronic HF; (2) compare the clinical and demographic characteristics between groups with COMISA, insomnia, SDB, and normal sleep; and (3) examine the risk of COMISA in the presence of normal sleep, insomnia, SDB and other clinical and demographic characteristics. Methods Secondary analysis of an observational study of sleep among adults with stable HF. COMISA was defined as an apnea hypopnea index (AHI) > 15 with difficulty initiating or maintaining sleep or waking too early in the morning (Insomnia). We measured self-reported (Pittsburgh Sleep Quality Index) and objective sleep characteristics (polysomnography – PSG), symptoms (depression, sleepiness); used chi-square and ANOVA; and calculated the risks of COMISA for normal sleepers and with insomnia or SDB under different conditions (depression, poor sleep quality, left ventricular ejection fraction, age, race, and sex). Results The sample included 170 [(M age = 60.3 ± 16.8 years; n = 60 (35%] female. They had normal sleep (n = 37/22%); insomnia only (n = 48/28%): SDB only (n = 46/27%); and COMISA (n = 39/23%). Those with COMISA were significantly more likely to be obese (32.1%) compared to others [13.6% -29.6%, p = 0.0128]. They had the shortest total sleep time (TST) (mean = 291 ± 109 mins) and poorest sleep efficiency (M = 65.8 ± 20.5%) (p = .05). Women with insomnia were less likely to have COMISA than men (36% vs. 51%), while 74% of adults with SDB who were depressed had COMISA, compared with 41% of those with insomnia. Conclusion Risk of COMISA is associated with depression and poor sleep among adults with stable HF and SDB. Future study is needed to better understand the risks of COMISA among adults with chronic HF outcomes and to address the need for intervention that addresses it beyond a focus on only SDB or insomnia. Support (if any)
0657 Understanding the Debilitating Nature of Narcolepsy in Patients’ Own Words: A Social Listening Analysis
Lavender, Maggie, Horsnell, Matthew , Krahn, Lois E., Cronin, Dianna, Schneider, Beth, Gudeman, Jennifer , Morse, Anne Marie , Ortiz, Luis, Schneider, Beth

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A281-A281

10.1093/sleep/zsae067.0657 Get It

Abstract Introduction To further characterize the many struggles and unmet needs of people with narcolepsy (PWN), passive social listening was used to explore how PWN describe the condition using their own words. Methods MyNarcolepsyTeam is a social network where members can organically share their experiences living with narcolepsy with one another. Following an online survey, organic posts, comments, questions, and answers posted from January 2022 to present were analyzed. Results Of 110 survey respondents, 31% reported that the time from symptom onset to diagnosis was ≥10 years. Social listening highlighted both misdiagnoses (eg, depression) and “missed” diagnoses (eg, sleep apnea but not narcolepsy). Almost half (43%) of respondents reported pain as a comorbidity. Social listening revealed the burden of painful comorbidities (eg, fibromyalgia, migraines, neuropathy), which often lead to additional medications and further sleep disruption. While 90% of respondents reported excessive daytime sleepiness, 81% also reported sleep disturbances. Nighttime disruptions experienced by PWN included poor sleep quality, vivid dreams, frequent awakenings, sleep paralysis, and abnormal REM cycles. Structured routines helped improve sleep for some PWN. Additionally, 33% of respondents reporting cataplexy always experienced full body cataplexy; 21% always experienced localized cataplexy; 43% experienced a mix of both, with the remaining answering ‘not sure.’ Social listening highlighted the dangers of cataplexy, including falls/fractures. Organic conversations also brought to bear the full range of emotions that can trigger an attack – from laughter, to being startled, to feeling stressed. In total, 65% of respondents were taking ≥2 medications to treat daytime and/or nighttime narcolepsy symptoms. Organic conversations highlighted the challenges PWN experience managing complex treatment regimens in an attempt to cope with the full spectrum of narcolepsy symptoms. Conclusion Insight into how narcolepsy is experienced in patients’ own words and how patients try to mitigate their symptoms will help sleep specialists better understand the challenges and needs of PWN, which can lead to both faster diagnosis and more effective, individualized treatment. Support (if any) Avadel Pharmaceuticals